| HOME >> MEDICINE >> TECHNOLOGY |
William R. LaRue
Kelli KampanisSVP & Chief Financial Officer
Media RelationsCadence Pharmaceuticals, Inc.
WCGPhone: 858-436-1400
Phone: 310-625-3248CADENCE PHARMACEUTICALS, INC.(a development stage company)CONDENSED STATEMENTS OF OPERATIONS(unaudited)(in thousands except per share amounts)Three Months EndedTwelve Months EndedDecember 31,December 31,2010200920102009Operating expenses:Research and development
$
3,192$
4,780$
3,757$
9,464Sales and marketing
11,5976,93926,45511,729General and administrative
3,3663,34212,89212,891Other
31-1,813413Total operating expenses
18,18615,06154,91744,497Loss from operations
(18,186)(15,061)(54,917)(44,497)Other expense, net
(607)(251)(1,726)(994)Net loss
$
(18,793)$
(15,312)$
(56,643)$
(45,491)Basic and diluted net lossper share(1)
$
(0.33)$
(0.30)$
(1.09)$
(0.93)Shares used to compute basic anddiluted net loss per share(1)
56,53150,43052,04248,754(1) As a result of the issuance of 12,500 shares of common stock pursuant to a public offering in the fourth quarter of 2010 and the issuance of 12,040 shares pursuant to a private placement in the first quarter of 2009, there is a lack of comparability in the per share amounts between the three and twelve month periods presented. CADENCE PHARMACEUTICALS, INC.(a development stage company)CONDENSED BALANCE SHEETS(in thousands)December 31,December 31,2010 2009 (unaudited)AssetsCurrent assets:Cash, cash equivalents and short-term investments
$
34,141$
82,006Restricted cash
1501,498Inventory
485-Prepaid expenses and other current assets
1,268549Total current assets
136,04484,053Property and equipment, net
8,9868,300Intangible assets
15,000-Restricted cash
190190Other assets
'/>"/>| SOURCE Cadence Pharmaceuticals, Inc. Copyright©2010 PR Newswire. All rights reserved |